Guided Therapeutics (GTHP) Equity Average (2016 - 2025)
Guided Therapeutics (GTHP) has disclosed Equity Average for 14 consecutive years, with -$5.8 million as the latest value for Q4 2025.
- Quarterly Equity Average fell 19.3% to -$5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.8 million through Dec 2025, down 19.3% year-over-year, with the annual reading at -$5.4 million for FY2025, 25.23% down from the prior year.
- Equity Average hit -$5.8 million in Q4 2025 for Guided Therapeutics, down from -$5.6 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of -$2.8 million in Q4 2022 to a low of -$9.4 million in Q1 2021.
- Historically, Equity Average has averaged -$5.1 million across 5 years, with a median of -$4.9 million in 2024.
- Biggest five-year swings in Equity Average: surged 58.05% in 2022 and later plummeted 40.66% in 2024.
- Year by year, Equity Average stood at -$6.6 million in 2021, then soared by 58.05% to -$2.8 million in 2022, then plummeted by 34.73% to -$3.7 million in 2023, then tumbled by 31.53% to -$4.9 million in 2024, then dropped by 19.3% to -$5.8 million in 2025.
- Business Quant data shows Equity Average for GTHP at -$5.8 million in Q4 2025, -$5.6 million in Q3 2025, and -$5.2 million in Q2 2025.